Varghese Elizabeth, Samuel Samson Mathews, Hornak Slavomir, Kubatka Peter, Büsselberg Dietrich
Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha P.O. Box 24144, Qatar.
Laboratory of Clinical and Regenerative Medicine, Small Animal Clinic, University of Veterinary Medicine and Pharmacy in Kosice 041 81 Kosice, Slovakia.
J Adv Res. 2025 Sep 4. doi: 10.1016/j.jare.2025.08.052.
Studies on the interaction of cancer cells with other cells (fibroblasts, endothelial cells, and immune cells) of the tumor microenvironment (TME) have led to the development of many novel targeted therapies. More recently, the notion that neuronal cells of the TME could impact various processes supporting cancer progression has gained momentum. Tumor-associated neurons release neurotransmitters into the TME that, in turn, bind to specific receptors on different target cells, supporting cancer progression. Furthermore, cancer cells secrete nerve growth factors and neurotropic factors that facilitate the growth of nerve fibers that innervate the tumor. In this regard, the beta 2-adrenergic receptors (β2-AR), which respond to neurotropic factors such as catecholamines, are highly expressed in cancer cells, including colorectal cancer (CRC).
Understanding the complexity of the neuronal-cancer axis and identifying targets for molecular therapy is essential. This review focuses on the role of β2-AR in neuro-neoplastic cell signaling during CRC progression and its clinical relevance to diagnosis, prognosis, and treatment.
The expression of β2-AR on CRC and various other cells of the colorectal TME, along with its responsiveness to agonists or antagonists, is of particular interest since targeting β2-AR and related pathways could curb CRC growth. In the current article, we provide an in-depth review of the possible central role of β2-AR in CRC cancer progression, with special reference to stress-induced activation of the nervous system, catecholamine release, hyperactivation of adrenergic signaling concerning the activation of downstream oncogenic pathways, immuno-modulation, and metastasis. The article also emphasizes the clinical significance of β2-AR expression, its potential as a diagnostic/prognostic biomarker, and the benefits of targeting (by repurposing β-blockers) β2-AR in combination therapies to improve the therapeutic efficacy of current treatment options and overall patient outcomes.
